Further pharmacological studies in animal models of colitis demonstrated that synthetic solomonsterol A effectively protects against development of clinical signs and symptoms of colitis and reduces the generation of TNFα, a signature cytokine for this disorder [232]. The gene discussed is TNF; the disease is colitis.